Compare Moderna, Inc. (MRNA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Moderna, Inc. is far larger — about 36.8× Recursion Pharmaceuticals Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MRNA | RXRX | |
|---|---|---|
Market Cap | $78.65B | $2.14B |
Volume | 37,373,437 | 30,789,535 |
Sector | Health | Health |
52-Week High | $203.46 | $6.79 |
52-Week Low | $22.36 | $2.84 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
